Nanobiotix Raises €85M in Oversubscribed Global Offering
Event summary
- Nanobiotix priced an €85M global offering, including €73.4M from U.S. and international shares and €11.6M from pre-funded warrants.
- The offering was oversubscribed, with proceeds expected to extend the company's cash runway into 2029.
- Key investors including Qatar Holding LLC and Invus supported the transaction.
- The offering included a 30-day over-allotment option for underwriters to purchase additional ADSs.
- Shares are expected to resume trading on Euronext and Nasdaq on May 26, 2026.
The big picture
Nanobiotix's €85M raise underscores the continued appetite for late-stage biotech financing, even amid market volatility. The oversubscription suggests confidence in the company's physics-based oncology platforms, though the 14.92% discount highlights investor caution. With proceeds aimed at extending its cash runway into 2029, the offering positions Nanobiotix to navigate potential funding gaps in a competitive biotech landscape.
What we're watching
- Proceeds Allocation
- How Nanobiotix allocates the €85M across JNJ-1900 development, Nanoprimer platform, and general corporate purposes will signal strategic priorities.
- Market Reaction
- Whether the 14.92% discount to the 3-day average share price stabilizes or triggers further volatility in Nanobiotix's stock.
- Dilution Impact
- The pace at which existing shareholders' equity per share recovers post-dilution, particularly for non-participating investors.
Related topics